Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Consensus Rating of “Hold” by Brokerages

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) have been assigned a consensus rating of “Hold” from the six analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $3.2250.

LXRX has been the topic of a number of recent research reports. Wall Street Zen lowered Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, January 22nd.

Insider Buying and Selling at Lexicon Pharmaceuticals

In other news, Director Invus Global Management, Llc purchased 1,538,462 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were acquired at an average cost of $1.30 per share, for a total transaction of $2,000,000.60. Following the completion of the purchase, the director directly owned 1,538,462 shares in the company, valued at $2,000,000.60. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 13.90% of the stock is currently owned by insiders.

Institutional Trading of Lexicon Pharmaceuticals

Hedge funds have recently modified their holdings of the business. UBS Group AG grew its holdings in Lexicon Pharmaceuticals by 752.1% during the fourth quarter. UBS Group AG now owns 3,007,237 shares of the biopharmaceutical company’s stock worth $3,458,000 after acquiring an additional 2,654,315 shares during the period. CIBC Bancorp USA Inc. purchased a new stake in shares of Lexicon Pharmaceuticals during the 3rd quarter worth $3,240,000. Millennium Management LLC grew its stake in shares of Lexicon Pharmaceuticals by 133.1% during the 3rd quarter. Millennium Management LLC now owns 3,830,660 shares of the biopharmaceutical company’s stock worth $5,171,000 after purchasing an additional 2,187,396 shares during the period. Marshall Wace LLP acquired a new stake in shares of Lexicon Pharmaceuticals in the fourth quarter valued at about $1,452,000. Finally, AQR Capital Management LLC purchased a new stake in shares of Lexicon Pharmaceuticals during the 1st quarter worth approximately $541,000. 74.70% of the stock is owned by institutional investors and hedge funds.

Lexicon Pharmaceuticals Price Performance

Shares of LXRX opened at $1.52 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 5.63 and a current ratio of 5.64. Lexicon Pharmaceuticals has a fifty-two week low of $0.28 and a fifty-two week high of $1.83. The firm has a 50-day simple moving average of $1.29 and a 200-day simple moving average of $1.30. The company has a market capitalization of $552.47 million, a price-to-earnings ratio of -8.00 and a beta of 0.98.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.